Cochrane · systematic review · CD009151
Treatment for recurrent vulvovaginal candidiasis (thrush)
Cooke, G, Watson, C, Deckx, L, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Sexually Transmitted InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 25%Very low 4 · 50%Low 2 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Drug treatment compared to placebo or no treatment for recurrent vulvovaginal candidiasis
Population: non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome 1: Number of clinical recurrences per participant per year Drug treatment vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Primary outcome 2: Clinical recurrence at 6 months Drug treatment vs placebo or no treatment | RR 0.36 [0.21, 0.63] | 6 studies · 607 participants | Low Downgraded: risk of bias |
Primary outcome 2: Clinical recurrence at 12 months Drug treatment vs placebo or no treatment | RR 0.8 [0.72, 0.89] | 6 studies · 585 participants | Low Downgraded: risk of bias |
Primary outcome 3: Adverse events Drug treatment vs placebo or no treatment | no estimate extracted | 5 studies · 5 participants | Very low Downgraded: risk of bias, imprecision |
Oral drug treatment compared to topical drug treatment for recurrent vulvovaginal candidiasis
Population: non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome 1: Number of clinical recurrences per participant per year Oral drug treatment vs topical drug treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Primary outcome 2: Clinical recurrence at 6 months Oral drug treatment vs topical drug treatment | RR 1.66 [0.83, 3.31] | 3 studies · 206 participants | Very low Downgraded: risk of bias, imprecision |
Primary outcome 2: Clinical recurrence at 12 months Oral drug treatment vs topical drug treatment | RR 0.95 [0.71, 1.27] | 3 studies · 206 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Primary outcome 3: Adverse events Oral drug treatment vs topical drug treatment | no estimate extracted | 3 studies · 3 participants | Very low Downgraded: risk of bias, imprecision |